The goal of this clinical trial is to provide continued access to GLM101 to treat PMM2-CDG in people who have previously received GLM101 in other trials and lea…

Spain, United Kingdom90 participantsStarted 2024-09-30

Treatment: GLM101

Active — Not RecruitingPhase 2/3

NCT06892288

A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including chil…

United States, Belgium50 participantsStarted 2025-07-09

Treatment: GLM101 (Part A, Double-blind), Placebo (Part A, Double-blind)

Pmm2-CDG

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Clinical and Basic Investigations Into Congenital Disorders of Glycosylation

All recent trials (7 shown)

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Clinical and Basic Investigations Into Congenital Disorders of Glycosylation

All recent trials (7 shown)

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

Natural History Study Protocol in PMM2-CDG (CDG-Ia)

Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

Acetazolamide Efficacy in Ataxia in PMM2-CDG